drugset / Trial / NCT06273215

Evaluation of the Pharmacokinetics of Microdose Midazolam, Dabigatran, Pitavastatin, Atorvastatin and Rosuvastatin in Diabetic Patients

NCT06273215

Phase 4 Unknown 48 enrolled Peking University Third Hospital
Non-randomizedParallel-groupOpen-labelBasic science

Summary

1.To explore the functional changes of P-gp, CYP3A4, OATP1B and BCRP in Diabetic patients (including the non-obese T2DM, obese T2DM, elderly T2DM, and T1DM).

Timeline

Start
2023-03-05
Primary completion
2025-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 100 ug
Subject Dabigatran etexilate Unknown 375 ug
Subject Midazolam Small molecule 10 ug
Subject Pitavastatin Small molecule 10 ug
Subject Rosuvastatin Small molecule 50 ug

Indications